Life sciences briefing: Tuesday, Nov. 13, 2007
Featured companies: Akermin, Fluxion Biosciences, iCardiacTechnologies, Wellocities
UPDATED: Expanded items on Fluxion, Akermin, and Wellocities.
Fluxion Bio draws in $6.9M for cell-analysis tools — Fluxion Biosciences, a San Francisco developer of cellular-analysis tools, raised $6.9 million in a second funding round, VentureWire reports (subscription required). Investors included Kodiak Venture Partners, Claremont Creek Ventures and Life Science Angels.
Fluxion takes the idea of running chemical reactions against living cells — a key step in screening and analyzing the activity of drug… Continue Reading
Life sciences briefing: Wednesday, Oct. 3, 2007
Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics
Heart-diagnostic maker Aviir raises $11.3M — Palo Alto, Calif.-based Aviir, a biotech developing cardiovascular diagnostics based on Stanford research, raised $11.3 million of an expected $25 million second funding round, PE Hub reports. The news is presumably from one of those paper-based SEC filings that are supposed to be digitized before long.
Investors include Bay City Capital, Aberdare Ventures and New Leaf Ventures. Aviir hasn’t said much about its technology… Continue Reading